Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma

BET-bromodomain inhibition (BETi) has shown pre-clinical promise for MYC-amplified medulloblastoma. However, the mechanisms for its action, and ultimately for resistance, have not been fully defined. Here, using a combination of expression profiling, genome-scale CRISPR/Cas9-mediated loss of functio...

Full description

Bibliographic Details
Main Authors: Bandopadhayay, Pratiti, Piccioni, Federica, O’Rourke, Ryan, Ho, Patricia, Gonzalez, Elizabeth M., Buchan, Graham, Qian, Kenin, Gionet, Gabrielle, Girard, Emily, Coxon, Margo, Rees, Matthew G., Brenan, Lisa, Dubois, Frank, Shapira, Ofer, Greenwald, Noah F., Pages, Melanie, Balboni Iniguez, Amanda, Paolella, Brenton R., Meng, Alice, Sinai, Claire, Roti, Giovanni, Dharia, Neekesh V., Creech, Amanda, Tanenbaum, Benjamin, Khadka, Prasidda, Tracy, Adam, Tiv, Hong L., Hong, Andrew L., Coy, Shannon, Rashid, Rumana, Lin, Jia-Ren, Cowley, Glenn S., Lam, Fred Chiu-Lai, Goodale, Amy, Lee, Yenarae, Schoolcraft, Kathleen, Vazquez, Francisca, Hahn, William C., Tsherniak, Aviad, Bradner, James E., Yaffe, Michael B, Milde, Till, Pfister, Stefan M., Qi, Jun, Schenone, Monica, Carr, Steven A., Ligon, Keith L., Kieran, Mark W., Santagata, Sandro, Olson, James M., Gokhale, Prafulla C., Jaffe, Jacob D., Root, David E., Stegmaier, Kimberly, Johannessen, Cory M., Beroukhim, Rameen
Other Authors: Koch Institute for Integrative Cancer Research at MIT
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2020
Online Access:https://hdl.handle.net/1721.1/125375